Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2013 (2013), Article ID 580404, 7 pages
http://dx.doi.org/10.1155/2013/580404
Research Article

Psoriatic Arthritis and Diabetes: A Population-Based Cross-Sectional Study

1Clalit Health Services, Faculty of Health Sciences, Ben-Gurion University of the Negev, 84150 Beer-Sheva, Israel
2Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, 84150, Israel

Received 14 March 2013; Accepted 16 May 2013

Academic Editor: Pablo Coto-Segura

Copyright © 2013 Jacob Dreiher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Christophers, “Psoriasis—epidemiology and clinical spectrum,” Clinical and Experimental Dermatology, vol. 26, no. 4, pp. 314–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. F. C. Wilson, M. Icen, C. S. Crowson, M. T. McEvoy, S. E. Gabriel, and H. M. Kremers, “Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study,” Journal of Rheumatology, vol. 36, no. 2, pp. 361–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Han, D. W. Robinson Jr., M. V. Hackett, L. C. Paramore, K. H. Fraeman, and M. V. Bala, “Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis,” Journal of Rheumatology, vol. 33, no. 11, pp. 2167–2172, 2006. View at Google Scholar · View at Scopus
  4. O. Kimhi, D. Caspi, N. M. Bornstein et al., “Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis,” Seminars in Arthritis and Rheumatism, vol. 36, no. 4, pp. 203–209, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Henseler and E. Christophers, “Disease concomitance in psoriasis,” Journal of the American Academy of Dermatology, vol. 32, no. 6, pp. 982–986, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Shapiro, A. D. Cohen, M. David et al., “The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A Case-Control Study,” Journal of the American Academy of Dermatology, vol. 56, no. 4, pp. 629–634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Lindegard, “Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes,” Dermatologica, vol. 172, no. 6, pp. 298–304, 1986. View at Google Scholar · View at Scopus
  8. A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand, “Prevalence of cardiovascular risk factors in patients with psoriasis,” Journal of the American Academy of Dermatology, vol. 55, no. 5, pp. 829–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Pearce, A. E. Morrison, K. B. Higgins et al., “The comorbid state of psoriasis patients in a university dermatology practice,” Journal of Dermatological Treatment, vol. 16, no. 5-6, pp. 319–323, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal, “Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis,” Archives of Dermatological Research, vol. 298, no. 7, pp. 321–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Cohen, J. Dreiher, Y. Shapiro et al., “Psoriasis and diabetes: a population-based cross-sectional study,” Journal of the European Academy of Dermatology and Venereology, vol. 22, no. 5, pp. 585–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Späh, “Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach,” British Journal of Dermatology, vol. 159, supplement 2, pp. 10–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. B. Kimball, D. Robinson Jr., Y. Wu et al., “Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002,” Dermatology, vol. 217, no. 1, pp. 27–37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Wu, D. Mills, and M. Bala, “Psoriasis: cardiovascular risk factors and other disease comorbidities,” Journal of Drugs in Dermatology, vol. 7, no. 4, pp. 373–377, 2008. View at Google Scholar · View at Scopus
  15. L. Mallbris, C. T. Ritchlin, and M. Ståhle, “Metabolic disorders in patients with psoriasis and psoriatic arthritis,” Current Rheumatology Reports, vol. 8, no. 5, pp. 355–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. A. B. Gottlieb, F. Dann, and A. Menter, “Psoriasis and the metabolic syndrome,” Journal of Drugs in Dermatology, vol. 7, no. 6, pp. 563–572, 2008. View at Google Scholar · View at Scopus
  17. A. A. Qureshi, H. K. Choi, A. R. Setty, and G. C. Curhan, “Psoriasis and the risk of diabetes and hypertension: a prospective study of us female nurses,” Archives of Dermatology, vol. 145, no. 4, pp. 379–382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Johnsson, I. B. McInnes, and N. Sattar, “Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence,” Annals of the Rheumatic Diseases, vol. 71, no. 4, pp. 480–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Peters, I. E. Van Der Horst-Bruinsma, B. A. Dijkmans, and M. T. Nurmohamed, “Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis,” Seminars in Arthritis and Rheumatism, vol. 34, no. 3, pp. 585–592, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. M. Farragher and I. N. Bruce, “Cardiovascular risk in inflammatory rheumatic diseases: loose ends and common threads,” Journal of Rheumatology, vol. 33, no. 11, pp. 2105–2107, 2006. View at Google Scholar · View at Scopus
  21. S. Armesto, J. Santos-Juanes, C. Galache-Osuna, P. Martinez-Camblor, E. Coto, and P. Coto-Segura, “Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population,” Australasian Journal of Dermatology, vol. 53, no. 2, pp. 128–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C. P. Chung, I. Avalos, A. Oeser et al., “High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors,” Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 208–214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. P. Chung, A. Oeser, J. F. Solus et al., “Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis,” Atherosclerosis, vol. 196, no. 2, pp. 756–763, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. C. C. Mok, G. T. C. Ko, L. Y. Ho, K. L. Yu, P. T. Chan, and C. H. To, “Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis,” Arthritis Care and Research, vol. 63, no. 2, pp. 195–202, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. L. S. Tam, B. Tomlinson, T. T. W. Chu et al., “Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation,” Rheumatology, vol. 47, no. 5, pp. 718–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Rennert and Y. Peterburg, “Prevalence of selected chronic diseases in Israel,” Israel Medical Association Journal, vol. 3, no. 6, pp. 404–408, 2001. View at Google Scholar · View at Scopus
  27. S. Vinker, Y. Fogelman, A. Elhayany, S. Nakar, and E. Kahan, “Usefulness of electronic databases for the detection of unrecognized diabetic patients,” Cardiovascular Diabetology, vol. 2, article 13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. B. H. Hahn, J. Grossman, W. Chen, and M. McMahon, “The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia,” Journal of Autoimmunity, vol. 28, no. 2-3, pp. 69–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. H. Solomon, T. J. Love, C. Canning, and S. Schneeweiss, “Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis,” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2114–2117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Franconi, G. Seghieri, S. Canu, E. Straface, I. Campesi, and W. Malorni, “Are the available experimental models of type 2 diabetes appropriate for a gender perspective?” Pharmacological Research, vol. 57, no. 1, pp. 6–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Saltevo, M. Vanhala, H. Kautiainen, E. Kumpusalo, and M. Laakso, “Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: A Population-Based Study,” Diabetic Medicine, vol. 25, no. 6, pp. 747–750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Gulliver, “Long-term prognosis in patients with psoriasis,” British Journal of Dermatology, vol. 159, supplement 2, pp. 2–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. W. H. Boehncke and S. Boehncke, “Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences,” Giornale Italiano di Dermatologia e Venereologia, vol. 143, no. 5, pp. 307–313, 2008. View at Google Scholar · View at Scopus
  34. Y. Liu, C. Helms, W. Liao et al., “A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci,” PLoS Genetics, vol. 4, no. 4, Article ID e1000041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. S. Yudkin, “Insulin resistance and the metabolic syndrome—or the pitfalls of epidemiology,” Diabetologia, vol. 50, no. 8, pp. 1576–1586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. E. Sonnenberg, G. R. Krakower, and A. H. Kissebah, “A novel pathway to the manifestations of metabolic syndrome,” Obesity Research, vol. 12, no. 2, pp. 180–186, 2004. View at Google Scholar · View at Scopus
  37. J. Channual, J. J. Wu, and F. J. Dann, “Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis,” Dermatologic Therapy, vol. 22, no. 1, pp. 61–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Yoo, S. Kim, Y. Kim, H. Lee, and T. Kim, “Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 6, pp. 1248–1259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. K. Das and S. C. Elbein, “The search for type 2 diabetes susceptibility loci: the chromosome 1q story,” Current Diabetes Reports, vol. 7, no. 2, pp. 154–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Steinthorsdottir, G. Thorleifsson, I. Reynisdottir et al., “A variant in CDKAL1 influences insulin response and risk of type 2 diabetes,” Nature Genetics, vol. 39, no. 6, pp. 770–775, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Wolf, M. Quaranta, N. J. Prescott et al., “Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease,” Journal of Medical Genetics, vol. 45, no. 2, pp. 114–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. W. H. Boehncke and W. Sterry, “Psoriasis—a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 7, no. 11, pp. 946–952, 2009. View at Publisher · View at Google Scholar
  43. T. Bongartz, B. Coras, T. Vogt, J. Schölmerich, and U. Müller-Ladner, “Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study,” Rheumatology, vol. 44, no. 1, pp. 126–129, 2005. View at Publisher · View at Google Scholar · View at Scopus